

Special Issue

Pharmacodynamic and Pharmacokinetics of Antibiotics in the Critically Ill

Message from the Guest Editor

Patients both in wards and in intensive care units (ICU) often develop severe infections which are associated with significant mortality rates. Recent and novel technologies for the microbiological diagnosis of these infections have been developed and significantly assist in ensuring the adequacy of antibiotic treatments. Unfortunately, treatment of bacterial infections may be complicated by alterations in the pharmacokinetics (PK) and pharmacodynamics (PD) of antimicrobial agents. Several tools have been developed or are in development for the quantification of antimicrobial concentrations even within a few hours after sample collection. Antibiotic efficacy may be affected by specific and single antibiotics as well as patient covariate data; therefore, therapeutic drug monitoring (TDM), when available and fast provided, gives the clinicians bedside help to improve antibiotic treatment quality and adequacy.

Guest Editor

Prof. Dr. Alberto Corona

Department of Accident & Emergency and Intensive Care Medicine
ASST Valcamonica, Esine & Edolo Hospital, Brescia, Italy

Deadline for manuscript submissions

closed (31 October 2022)



Antibiotics

an Open Access Journal
by MDPI

Impact Factor 4.6
CiteScore 8.7
Indexed in PubMed



mdpi.com/si/97143

Antibiotics
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
antibiotics@mdpi.com

[mdpi.com/journal/
antibiotics](https://mdpi.com/journal/antibiotics)





Antibiotics

an Open Access Journal
by MDPI

Impact Factor 4.6
CiteScore 8.7
Indexed in PubMed



[mdpi.com/journal/
antibiotics](https://mdpi.com/journal/antibiotics)



About the Journal

Message from the Editor-in-Chief

There are very few fields that attract as much attention as scientific endeavor related to antibiotic discovery, use and preservation. The public, patients, scientists, clinicians, policy-makers, NGOs, governments, and supra-governmental organizations are all focusing intensively on it: all are concerned that we use our existing agents more effectively, and develop and evaluate new interventions in time to face emerging challenges for the benefit of present and future generations. We need every discipline to contribute and collaborate: molecular, microbiological, clinical, epidemiological, geographic, economic, social scientific and policy disciplines are all key. *Antibiotics* is a nimble, inclusive and rigorous indexed journal as an enabling platform for all who can contribute to solving the greatest broad concerns of the modern world.

Editor-in-Chief

Prof. Dr. Nicholas Dixon
School of Chemistry and Molecular Bioscience, University of
Wollongong, Wollongong, NSW 2522, Australia

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Infectious Diseases) / CiteScore - Q1 (General Pharmacology, Toxicology and Pharmaceutics)